PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27278287-0	2016	Histone deacetyltransferase inhibitors Trichostatin A and Mocetinostat differentially regulate MMP9, IL-18 and RECK expression, and attenuate Angiotensin II-induced cardiac fibroblast migration and proliferation.	mocetinostat	58-70	matrix metallopeptidase 9	Mus musculus	95-99
27278287-0	2016	Histone deacetyltransferase inhibitors Trichostatin A and Mocetinostat differentially regulate MMP9, IL-18 and RECK expression, and attenuate Angiotensin II-induced cardiac fibroblast migration and proliferation.	mocetinostat	58-70	interleukin 18	Mus musculus	101-106
27278287-0	2016	Histone deacetyltransferase inhibitors Trichostatin A and Mocetinostat differentially regulate MMP9, IL-18 and RECK expression, and attenuate Angiotensin II-induced cardiac fibroblast migration and proliferation.	mocetinostat	58-70	reversion-inducing-cysteine-rich protein with kazal motifs	Mus musculus	111-115
27283770-6	2016	Moreover, MGCD-induced apoptosis was decreased by inhibition of p53 using short interfering RNA (siRNA), suggesting that p53 was required for MGCD-induced cell apoptosis.	mocetinostat	10-14	tumor protein p53	Homo sapiens	64-67
27278287-9	2016	The class I-specific HDAC inhibitor Mocetinostat (MGCD) recapitulated TSA effects on Ang-II-treated CF.	mocetinostat	36-48	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	85-91
27283770-6	2016	Moreover, MGCD-induced apoptosis was decreased by inhibition of p53 using short interfering RNA (siRNA), suggesting that p53 was required for MGCD-induced cell apoptosis.	mocetinostat	10-14	tumor protein p53	Homo sapiens	121-124
27283770-6	2016	Moreover, MGCD-induced apoptosis was decreased by inhibition of p53 using short interfering RNA (siRNA), suggesting that p53 was required for MGCD-induced cell apoptosis.	mocetinostat	142-146	tumor protein p53	Homo sapiens	64-67
27283770-6	2016	Moreover, MGCD-induced apoptosis was decreased by inhibition of p53 using short interfering RNA (siRNA), suggesting that p53 was required for MGCD-induced cell apoptosis.	mocetinostat	142-146	tumor protein p53	Homo sapiens	121-124
27283770-7	2016	Consistently, MGCD in combination with Nutlin-3, a MDM2 inhibitor showed synergistic effect on inducing apoptosis in 2D and 3D cultured CNE2 cells.	mocetinostat	14-18	MDM2 proto-oncogene	Homo sapiens	51-55
27283770-8	2016	Collectively, our data revealed that MGCD induced p53-dependent cell apoptosis following formation of multipolar spindles in NPC cells, suggesting the therapeutic potential of combinations of HDACs and MDM2 inhibitors for NPC treatment.	mocetinostat	37-41	tumor protein p53	Homo sapiens	50-53
27283770-8	2016	Collectively, our data revealed that MGCD induced p53-dependent cell apoptosis following formation of multipolar spindles in NPC cells, suggesting the therapeutic potential of combinations of HDACs and MDM2 inhibitors for NPC treatment.	mocetinostat	37-41	MDM2 proto-oncogene	Homo sapiens	202-206
26721445-4	2016	The HDAC inhibitors vorinostat, mocetinostat and entinostat induced 400-600% hyperacetylation in HEK 293 and K562 cells.	mocetinostat	32-44	histone deacetylase 9	Homo sapiens	4-8
27551526-0	2016	Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6.	mocetinostat	23-35	histone deacetylase 9	Homo sapiens	8-12
27551526-0	2016	Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6.	mocetinostat	23-35	microRNA 31	Homo sapiens	71-77
27551526-0	2016	Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6.	mocetinostat	23-35	E2F transcription factor 6	Homo sapiens	108-112
27551526-2	2016	To understand how mocetinostat induces apoptosis, we examined the effects of mocetinostat on miR-31, a proapoptotic microRNA that was previously found to be epigenetically silenced in prostate cancer.	mocetinostat	77-89	microRNA 31	Homo sapiens	93-99
27551526-4	2016	Antiapoptotic protein E2F6, the target of miR-31, was decreased by mocetinostat treatment.	mocetinostat	67-79	E2F transcription factor 6	Homo sapiens	22-26
27551526-4	2016	Antiapoptotic protein E2F6, the target of miR-31, was decreased by mocetinostat treatment.	mocetinostat	67-79	microRNA 31	Homo sapiens	42-48
27551526-5	2016	When miR-31 was blocked with an inhibitor, the ability of mocetinostat to induce apoptosis was reduced.	mocetinostat	58-70	microRNA 31	Homo sapiens	5-11
27551526-7	2016	While siRNA knockdown of E2F6 sensitized cancer cells to mocetinostat-induced apoptosis, overexpression of E2F6 blocked mocetinostat-induced apoptosis.	mocetinostat	57-69	E2F transcription factor 6	Homo sapiens	25-29
27551526-7	2016	While siRNA knockdown of E2F6 sensitized cancer cells to mocetinostat-induced apoptosis, overexpression of E2F6 blocked mocetinostat-induced apoptosis.	mocetinostat	120-132	E2F transcription factor 6	Homo sapiens	107-111
27551526-8	2016	In an orthotopic xenograft model, we demonstrated that mocetinostat activated miR-31, decreased E2F6, induced apoptosis, and significantly reduced prostate cancer growth.	mocetinostat	55-67	microRNA 31	Homo sapiens	78-84
27551526-8	2016	In an orthotopic xenograft model, we demonstrated that mocetinostat activated miR-31, decreased E2F6, induced apoptosis, and significantly reduced prostate cancer growth.	mocetinostat	55-67	E2F transcription factor 6	Homo sapiens	96-100
27551526-9	2016	Importantly, we found that mocetinostat also increased miR-31 expression, decreased E2F6, and induced apoptosis in the primary prostate cancer stem cells.	mocetinostat	27-39	microRNA 31	Homo sapiens	55-61
27551526-9	2016	Importantly, we found that mocetinostat also increased miR-31 expression, decreased E2F6, and induced apoptosis in the primary prostate cancer stem cells.	mocetinostat	27-39	E2F transcription factor 6	Homo sapiens	84-88
27551526-10	2016	Thus, activation of miR-31 and downregulation of E2F6 constitute an important mechanism in mocetinostat-induced apoptosis in prostate cancer.	mocetinostat	91-103	microRNA 31	Homo sapiens	20-26
27551526-10	2016	Thus, activation of miR-31 and downregulation of E2F6 constitute an important mechanism in mocetinostat-induced apoptosis in prostate cancer.	mocetinostat	91-103	E2F transcription factor 6	Homo sapiens	49-53
25341045-4	2014	Further, knockdown of HDAC1 in leukemia cells K562, HL-60, and U937 significantly increased Klf4 expression and inhibited cell cycle progression and cell proliferation, similar results were found for HDAC inhibitors (VPA and mocetinostat).	mocetinostat	225-237	histone deacetylase 1	Homo sapiens	22-27
26091518-6	2015	Furthermore, we provided evidence that PPARgamma agonist is able to enhance the action of other HDACi such as Vorinostat or Mocetinostat.	mocetinostat	124-136	peroxisome proliferator activated receptor gamma	Homo sapiens	39-48
25872941-0	2015	ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.	mocetinostat	90-102	zinc finger E-box binding homeobox 1	Homo sapiens	0-4
25997003-0	2015	Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure.	mocetinostat	49-61	interleukin 6	Rattus norvegicus	81-85
25997003-0	2015	Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure.	mocetinostat	49-61	signal transducer and activator of transcription 3	Rattus norvegicus	86-91
25997003-10	2015	Cardiac fibroblasts isolated from Mocetinostat-treated CHF ventricles showed a decrease in expression of collagen I and III, fibronectin and Timp1.	mocetinostat	34-46	fibronectin 1	Rattus norvegicus	125-136
25997003-10	2015	Cardiac fibroblasts isolated from Mocetinostat-treated CHF ventricles showed a decrease in expression of collagen I and III, fibronectin and Timp1.	mocetinostat	34-46	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	141-146
25997003-13	2015	CONCLUSIONS: Anti-fibrotic effects of Mocetinostat in CHF are associated with the IL-6/STAT3 signaling pathway.	mocetinostat	38-50	interleukin 6	Rattus norvegicus	82-86
25997003-13	2015	CONCLUSIONS: Anti-fibrotic effects of Mocetinostat in CHF are associated with the IL-6/STAT3 signaling pathway.	mocetinostat	38-50	signal transducer and activator of transcription 3	Rattus norvegicus	87-92
26357656-2	2015	In order to investigate the effects of MGCD0103 on the metabolic capacity of cytochrome P450 (CYP) enzymes, a cocktail method was employed to evaluate the activities of human CYP2B1, CYP1A2, CYP2C11, CYP2D6, CYP3A4, and CYP2C9.	mocetinostat	39-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92
26357656-2	2015	In order to investigate the effects of MGCD0103 on the metabolic capacity of cytochrome P450 (CYP) enzymes, a cocktail method was employed to evaluate the activities of human CYP2B1, CYP1A2, CYP2C11, CYP2D6, CYP3A4, and CYP2C9.	mocetinostat	39-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97
26357656-7	2015	Continuous 7-day intragastric administration of MGCD0103 slightly induces the activities of CYP2C11 of rats.	mocetinostat	48-56	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	92-99
21171821-0	2011	Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.	mocetinostat	173-181	MAGE family member A3	Homo sapiens	25-32
24451378-9	2014	Our results demonstrate that trichostatin A and MGCD0103 enhanced Npr1 gene expression through inhibition of HDAC1/2 and increased both acetylation of histones (H3-K9/14, H4-K12) and Sp1 by p300, and their recruitment to Npr1 promoter.	mocetinostat	48-56	natriuretic peptide receptor 1	Mus musculus	66-70
24451378-9	2014	Our results demonstrate that trichostatin A and MGCD0103 enhanced Npr1 gene expression through inhibition of HDAC1/2 and increased both acetylation of histones (H3-K9/14, H4-K12) and Sp1 by p300, and their recruitment to Npr1 promoter.	mocetinostat	48-56	histone deacetylase 1	Mus musculus	109-116
24451378-9	2014	Our results demonstrate that trichostatin A and MGCD0103 enhanced Npr1 gene expression through inhibition of HDAC1/2 and increased both acetylation of histones (H3-K9/14, H4-K12) and Sp1 by p300, and their recruitment to Npr1 promoter.	mocetinostat	48-56	E1A binding protein p300	Mus musculus	190-194
24451378-9	2014	Our results demonstrate that trichostatin A and MGCD0103 enhanced Npr1 gene expression through inhibition of HDAC1/2 and increased both acetylation of histones (H3-K9/14, H4-K12) and Sp1 by p300, and their recruitment to Npr1 promoter.	mocetinostat	48-56	natriuretic peptide receptor 1	Mus musculus	221-225
21577204-7	2011	The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4.	mocetinostat	61-73	linker for activation of T cells family member 2	Homo sapiens	93-97
21577204-7	2011	The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4.	mocetinostat	61-73	RUNX family transcription factor 1	Homo sapiens	125-129
21577204-7	2011	The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4.	mocetinostat	61-73	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	130-133
21577204-7	2011	The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4.	mocetinostat	61-73	linker for activation of T cells family member 2	Homo sapiens	218-222
21577204-7	2011	The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4.	mocetinostat	75-83	linker for activation of T cells family member 2	Homo sapiens	93-97
21577204-7	2011	The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4.	mocetinostat	75-83	RUNX family transcription factor 1	Homo sapiens	125-129
21577204-7	2011	The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4.	mocetinostat	75-83	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	130-133
21577204-7	2011	The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4.	mocetinostat	75-83	linker for activation of T cells family member 2	Homo sapiens	218-222
24418989-0	2014	Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.	mocetinostat	61-69	histone deacetylase 9	Homo sapiens	31-50
24418989-3	2014	We have previously reported that the HDAC inhibitor MGCD0103 induces CLL cell death by activating the intrinsic pathway of apoptosis.	mocetinostat	52-60	histone deacetylase 9	Homo sapiens	37-41
25024745-0	2014	HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation.	mocetinostat	24-36	Thy-1 cell surface antigen	Rattus norvegicus	96-100
25024745-7	2014	Class I HDACs were selectively inhibited via Mocetinostat in CD90+ fibroblasts isolated from atrial and ventricular heart tissue in vitro.	mocetinostat	45-57	Thy-1 cell surface antigen	Rattus norvegicus	61-65
25024745-13	2014	In vitro treatment of CD90+ cells with Mocetinostat reversed myofibroblast phenotype as indicated by a decrease in alpha-Smooth muscle actin (alpha-SMA), Collagen III, and Matrix metalloproteinase-2 (MMP2).	mocetinostat	39-51	Thy-1 cell surface antigen	Rattus norvegicus	22-26
25024745-13	2014	In vitro treatment of CD90+ cells with Mocetinostat reversed myofibroblast phenotype as indicated by a decrease in alpha-Smooth muscle actin (alpha-SMA), Collagen III, and Matrix metalloproteinase-2 (MMP2).	mocetinostat	39-51	actin gamma 2, smooth muscle	Rattus norvegicus	115-140
25024745-13	2014	In vitro treatment of CD90+ cells with Mocetinostat reversed myofibroblast phenotype as indicated by a decrease in alpha-Smooth muscle actin (alpha-SMA), Collagen III, and Matrix metalloproteinase-2 (MMP2).	mocetinostat	39-51	actin gamma 2, smooth muscle	Rattus norvegicus	142-151
25024745-13	2014	In vitro treatment of CD90+ cells with Mocetinostat reversed myofibroblast phenotype as indicated by a decrease in alpha-Smooth muscle actin (alpha-SMA), Collagen III, and Matrix metalloproteinase-2 (MMP2).	mocetinostat	39-51	matrix metallopeptidase 2	Rattus norvegicus	172-198
25024745-13	2014	In vitro treatment of CD90+ cells with Mocetinostat reversed myofibroblast phenotype as indicated by a decrease in alpha-Smooth muscle actin (alpha-SMA), Collagen III, and Matrix metalloproteinase-2 (MMP2).	mocetinostat	39-51	matrix metallopeptidase 2	Rattus norvegicus	200-204
25024745-14	2014	Furthermore, Mocetinostat increased E-cadherin, induced beta-catenin localization to the membrane, and reduced Akt/GSK3beta signaling in atrial cardiac fibroblasts.	mocetinostat	13-25	cadherin 1	Rattus norvegicus	36-46
25024745-14	2014	Furthermore, Mocetinostat increased E-cadherin, induced beta-catenin localization to the membrane, and reduced Akt/GSK3beta signaling in atrial cardiac fibroblasts.	mocetinostat	13-25	catenin beta 1	Rattus norvegicus	56-68
25024745-14	2014	Furthermore, Mocetinostat increased E-cadherin, induced beta-catenin localization to the membrane, and reduced Akt/GSK3beta signaling in atrial cardiac fibroblasts.	mocetinostat	13-25	AKT serine/threonine kinase 1	Rattus norvegicus	111-114
25024745-14	2014	Furthermore, Mocetinostat increased E-cadherin, induced beta-catenin localization to the membrane, and reduced Akt/GSK3beta signaling in atrial cardiac fibroblasts.	mocetinostat	13-25	glycogen synthase kinase 3 beta	Rattus norvegicus	115-123
25024745-15	2014	In addition, Mocetinostat treatment of atrial CD90+ cells upregulated cleaved-Caspase3 and activated the p53/p21 axis.	mocetinostat	13-25	Thy-1 cell surface antigen	Rattus norvegicus	46-50
25024745-15	2014	In addition, Mocetinostat treatment of atrial CD90+ cells upregulated cleaved-Caspase3 and activated the p53/p21 axis.	mocetinostat	13-25	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	105-108
25024745-15	2014	In addition, Mocetinostat treatment of atrial CD90+ cells upregulated cleaved-Caspase3 and activated the p53/p21 axis.	mocetinostat	13-25	KRAS proto-oncogene, GTPase	Rattus norvegicus	109-112
24833798-8	2014	Nonselective class I HDAC inhibitors enhanced Arg2 expression, whereas the only selective inhibitor that increased Arg2 expression was mocetinostat, a selective inhibitor of HDACs 1 and 2.	mocetinostat	135-147	arginase 2	Homo sapiens	115-119
24451378-3	2014	Trichostatin A, a pan inhibitor, and mocetinostat (MGCD0103), a class I HDAC inhibitor, significantly enhanced Npr1 promoter activity (by 8- and 10-fold, respectively), mRNA levels (4- and 5.3-fold, respectively), and NPRA protein (2.7- and 3.5-fold, respectively).	mocetinostat	37-49	natriuretic peptide receptor 1	Mus musculus	111-115
24451378-3	2014	Trichostatin A, a pan inhibitor, and mocetinostat (MGCD0103), a class I HDAC inhibitor, significantly enhanced Npr1 promoter activity (by 8- and 10-fold, respectively), mRNA levels (4- and 5.3-fold, respectively), and NPRA protein (2.7- and 3.5-fold, respectively).	mocetinostat	37-49	natriuretic peptide receptor 1	Mus musculus	218-222
24451378-3	2014	Trichostatin A, a pan inhibitor, and mocetinostat (MGCD0103), a class I HDAC inhibitor, significantly enhanced Npr1 promoter activity (by 8- and 10-fold, respectively), mRNA levels (4- and 5.3-fold, respectively), and NPRA protein (2.7- and 3.5-fold, respectively).	mocetinostat	51-59	natriuretic peptide receptor 1	Mus musculus	111-115
24451378-3	2014	Trichostatin A, a pan inhibitor, and mocetinostat (MGCD0103), a class I HDAC inhibitor, significantly enhanced Npr1 promoter activity (by 8- and 10-fold, respectively), mRNA levels (4- and 5.3-fold, respectively), and NPRA protein (2.7- and 3.5-fold, respectively).	mocetinostat	51-59	natriuretic peptide receptor 1	Mus musculus	218-222
22908849-8	2012	The non-specific HDAC inhibitor trichostatin A elevated basal [Ca2+]i and enhanced Ca2+ storage, whereas the HDAC1/2/3 inhibitor MGCD0103 elevated basal [Ca2+]i without influence on Ca2+ storage in wild-type MEFs.	mocetinostat	129-137	histone deacetylase 1	Mus musculus	109-118
22818799-3	2012	More complex second generation HDACIs undergoing clinical trials, such as the benzamide group compounds MS-275 and MGCD0103, are specific primarily for HDAC1 and HDAC2.	mocetinostat	115-123	histone deacetylase 1	Homo sapiens	152-157
22818799-3	2012	More complex second generation HDACIs undergoing clinical trials, such as the benzamide group compounds MS-275 and MGCD0103, are specific primarily for HDAC1 and HDAC2.	mocetinostat	115-123	histone deacetylase 2	Homo sapiens	162-167
23251689-8	2012	Treatments with MGCD0103 (a class I-selective HDACI) resulted in dose-dependent growth arrest, cell death/apoptosis, and cell cycle arrest in G2/M phase, accompanied by induction of p21 and DNA double-strand breaks (DSBs).	mocetinostat	16-24	H3 histone pseudogene 16	Homo sapiens	182-185
23251689-11	2012	Although MC1568 or Tubastatin A alone had no obvious effects on DNA DSBs and p21 expression, their combination with MGCD0103 resulted in cooperative induction of p21 in the cells.	mocetinostat	116-124	H3 histone pseudogene 16	Homo sapiens	162-165
21317455-0	2010	The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling.	mocetinostat	27-35	histone deacetylase 9	Homo sapiens	12-16
20880107-0	2010	The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.	mocetinostat	27-35	histone deacetylase 6	Homo sapiens	133-138
20880107-4	2010	Furthermore, MGCD0103 induced tumour necrosis factor alpha (TNF-alpha) expression and secretion, which was associated with nuclear factor (NF)-kappaB activation.	mocetinostat	13-21	tumor necrosis factor	Homo sapiens	60-69
20880107-5	2010	Selective inhibition of TNF-alpha expression by short interfering mRNA, or inhibition of MGCD0103-induced NF-kB activation by proteasome inhibitors enhanced MGCD0103-induced cell death.	mocetinostat	157-165	tumor necrosis factor	Homo sapiens	24-33
20880107-6	2010	Thus, our results demonstrate that MGCD0103 may synergize with proteasome inhibitors by HDAC6-independent mechanisms, providing mechanistic rationale for exploring this potentially less toxic combination for the treatment of lymphoma.	mocetinostat	35-43	histone deacetylase 6	Homo sapiens	88-93
21317455-0	2010	The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling.	mocetinostat	27-35	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	125-135
17455259-4	2007	In contrast, the benzamides CI994, MS275 and MGCD0103 are more selective, potent inhibitors of at least HDAC1 and HDAC3.	mocetinostat	45-53	histone deacetylase 1	Homo sapiens	104-109
20406947-0	2010	The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade.	mocetinostat	34-42	histone deacetylase 9	Homo sapiens	4-23
20406947-0	2010	The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade.	mocetinostat	34-42	caspase 9	Homo sapiens	138-145
20406947-1	2010	Clinical trials have shown activity of the isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in different hematologic malignancies.	mocetinostat	98-106	histone deacetylase 9	Homo sapiens	61-80
20406947-1	2010	Clinical trials have shown activity of the isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in different hematologic malignancies.	mocetinostat	98-106	histone deacetylase 9	Homo sapiens	82-86
20406947-5	2010	MGCD0103 decreased the expression of Mcl-1 and induced translocation of Bax to the mitochondria, mitochondrial depolarization, and release of cytochrome c in the cytosol.	mocetinostat	0-8	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	37-42
20406947-5	2010	MGCD0103 decreased the expression of Mcl-1 and induced translocation of Bax to the mitochondria, mitochondrial depolarization, and release of cytochrome c in the cytosol.	mocetinostat	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	72-75
20406947-5	2010	MGCD0103 decreased the expression of Mcl-1 and induced translocation of Bax to the mitochondria, mitochondrial depolarization, and release of cytochrome c in the cytosol.	mocetinostat	0-8	cytochrome c, somatic	Homo sapiens	142-154
20406947-8	2010	Moreover, MGCD0103 treatment resulted in the activation of a caspase cascade downstream of caspase-9, caspase-dependent amplification of mitochondrial depolarization, activation of calpain, and Bax cleavage.	mocetinostat	10-18	caspase 9	Homo sapiens	61-68
20406947-8	2010	Moreover, MGCD0103 treatment resulted in the activation of a caspase cascade downstream of caspase-9, caspase-dependent amplification of mitochondrial depolarization, activation of calpain, and Bax cleavage.	mocetinostat	10-18	caspase 9	Homo sapiens	91-100
20406947-8	2010	Moreover, MGCD0103 treatment resulted in the activation of a caspase cascade downstream of caspase-9, caspase-dependent amplification of mitochondrial depolarization, activation of calpain, and Bax cleavage.	mocetinostat	10-18	caspase 9	Homo sapiens	91-98
20406947-8	2010	Moreover, MGCD0103 treatment resulted in the activation of a caspase cascade downstream of caspase-9, caspase-dependent amplification of mitochondrial depolarization, activation of calpain, and Bax cleavage.	mocetinostat	10-18	BCL2 associated X, apoptosis regulator	Homo sapiens	194-197
19747365-4	2009	MGCD0103 demonstrated pre-clinical activity against CLL cells with a LC(50) (concentration lethal to 50%) of 0.23 micromol/l and increased acetylation of the HDAC class I specific target histone H3.	mocetinostat	0-8	histone deacetylase 9	Homo sapiens	158-162
19775297-6	2009	Cell lines that had low expression level of HDAC6 demonstrated aberrant expression of hyper-acetylated tubulin, and were found to be more sensitive to the growth inhibitory effects of the class I HDAC inhibitor MGCD0103.	mocetinostat	211-219	histone deacetylase 6	Homo sapiens	44-49
19114304-0	2009	SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).	mocetinostat	93-167	sarcosine dehydrogenase	Homo sapiens	0-3
17868033-6	2008	MS-275 was HDAC1-selective, MGCD0103 was HDAC1- and HDAC2-selective, apicidin was HDAC2- and HDAC3-selective and valproic acid was a specific inhibitor of class I HDACs.	mocetinostat	28-36	histone deacetylase 1	Homo sapiens	41-46
19747365-0	2009	Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.	mocetinostat	52-60	histone deacetylase 9	Homo sapiens	22-41
19747365-1	2009	MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre-clinical activity in chronic lymphocytic leukaemia (CLL).	mocetinostat	0-8	histone deacetylase 9	Homo sapiens	38-57
19747365-1	2009	MGCD0103, an orally available class I histone deacetylase (HDAC) inhibitor, was examined for pre-clinical activity in chronic lymphocytic leukaemia (CLL).	mocetinostat	0-8	histone deacetylase 9	Homo sapiens	59-63
18413790-4	2008	We have developed an isotype-selective HDAC inhibitor, MGCD0103, which potently targets human HDAC1 but also has inhibitory activity against HDAC2, HDAC3, and HDAC11 in vitro.	mocetinostat	55-63	histone deacetylase 9	Homo sapiens	39-43
18413790-4	2008	We have developed an isotype-selective HDAC inhibitor, MGCD0103, which potently targets human HDAC1 but also has inhibitory activity against HDAC2, HDAC3, and HDAC11 in vitro.	mocetinostat	55-63	histone deacetylase 1	Homo sapiens	94-99
18413790-4	2008	We have developed an isotype-selective HDAC inhibitor, MGCD0103, which potently targets human HDAC1 but also has inhibitory activity against HDAC2, HDAC3, and HDAC11 in vitro.	mocetinostat	55-63	histone deacetylase 2	Homo sapiens	141-146
18413790-4	2008	We have developed an isotype-selective HDAC inhibitor, MGCD0103, which potently targets human HDAC1 but also has inhibitory activity against HDAC2, HDAC3, and HDAC11 in vitro.	mocetinostat	55-63	histone deacetylase 3	Homo sapiens	148-153
18413790-4	2008	We have developed an isotype-selective HDAC inhibitor, MGCD0103, which potently targets human HDAC1 but also has inhibitory activity against HDAC2, HDAC3, and HDAC11 in vitro.	mocetinostat	55-63	histone deacetylase 11	Homo sapiens	159-165
18413790-5	2008	In intact cells, MGCD0103 inhibited only a fraction of the total HDAC activity and showed long-lasting inhibitory activity even upon drug removal.	mocetinostat	17-25	histone deacetylase 9	Homo sapiens	65-69
18413790-7	2008	MGCD0103 exhibited potent and selective antiproliferative activities against a broad spectrum of human cancer cell lines in vitro, and HDAC inhibitory activity was required for these effects.	mocetinostat	0-8	histone deacetylase 9	Homo sapiens	135-139
18413790-9	2008	Our findings suggest that the isotype-selective HDAC inhibition by MGCD0103 is sufficient for antitumor activity in vivo and that further clinical investigation is warranted.	mocetinostat	67-75	histone deacetylase 9	Homo sapiens	48-52
17455259-4	2007	In contrast, the benzamides CI994, MS275 and MGCD0103 are more selective, potent inhibitors of at least HDAC1 and HDAC3.	mocetinostat	45-53	histone deacetylase 3	Homo sapiens	114-119
32373984-5	2020	In the current study, the effect of histone deacetylase (HDAC) inhibitor mocetinostat in a rat model of epidural fibrosis was detected, and it was discovered that mocetinostat suppressed myofibroblast activation and increased apoptosis by reducing Akt/GSK3b signaling.	mocetinostat	163-175	AKT serine/threonine kinase 1	Rattus norvegicus	248-251
34565105-0	2021	Histone deacetylase inhibitor, mocetinostat, regulates cardiac remodelling and renin-angiotensin system activity in rats with transverse aortic constriction-induced pressure overload cardiac hypertrophy.	mocetinostat	31-43	renin	Rattus norvegicus	79-84
35055045-6	2022	Treatment with the isoform-specific HDAC inhibitor mocetinostat, but not with PCI-34051, also increased BRN3A expression levels, suggesting that class I HDACs HDAC1, HDAC2, and HDAC3, and class IV HDAC11, were involved in the regulation of BRN3A expression.	mocetinostat	51-63	POU class 4 homeobox 1	Rattus norvegicus	104-109
35055045-6	2022	Treatment with the isoform-specific HDAC inhibitor mocetinostat, but not with PCI-34051, also increased BRN3A expression levels, suggesting that class I HDACs HDAC1, HDAC2, and HDAC3, and class IV HDAC11, were involved in the regulation of BRN3A expression.	mocetinostat	51-63	histone deacetylase 1	Rattus norvegicus	159-164
35055045-6	2022	Treatment with the isoform-specific HDAC inhibitor mocetinostat, but not with PCI-34051, also increased BRN3A expression levels, suggesting that class I HDACs HDAC1, HDAC2, and HDAC3, and class IV HDAC11, were involved in the regulation of BRN3A expression.	mocetinostat	51-63	histone deacetylase 2	Rattus norvegicus	166-171
35055045-6	2022	Treatment with the isoform-specific HDAC inhibitor mocetinostat, but not with PCI-34051, also increased BRN3A expression levels, suggesting that class I HDACs HDAC1, HDAC2, and HDAC3, and class IV HDAC11, were involved in the regulation of BRN3A expression.	mocetinostat	51-63	histone deacetylase 3	Rattus norvegicus	177-182
35055045-6	2022	Treatment with the isoform-specific HDAC inhibitor mocetinostat, but not with PCI-34051, also increased BRN3A expression levels, suggesting that class I HDACs HDAC1, HDAC2, and HDAC3, and class IV HDAC11, were involved in the regulation of BRN3A expression.	mocetinostat	51-63	histone deacetylase 11	Rattus norvegicus	197-203
35055045-6	2022	Treatment with the isoform-specific HDAC inhibitor mocetinostat, but not with PCI-34051, also increased BRN3A expression levels, suggesting that class I HDACs HDAC1, HDAC2, and HDAC3, and class IV HDAC11, were involved in the regulation of BRN3A expression.	mocetinostat	51-63	POU class 4 homeobox 1	Rattus norvegicus	240-245
34983914-0	2022	Isoform-selective HDAC Inhibitor Mocetinostat (MGCD0103) Alleviates Myocardial Ischemia/Reperfusion Injury via Mitochondrial Protection through the HDACs/CREB/PGC-1alpha Signaling Pathway.	mocetinostat	33-45	cAMP responsive element binding protein 1	Homo sapiens	154-158
34983914-0	2022	Isoform-selective HDAC Inhibitor Mocetinostat (MGCD0103) Alleviates Myocardial Ischemia/Reperfusion Injury via Mitochondrial Protection through the HDACs/CREB/PGC-1alpha Signaling Pathway.	mocetinostat	33-45	PPARG coactivator 1 alpha	Homo sapiens	159-169
34983914-0	2022	Isoform-selective HDAC Inhibitor Mocetinostat (MGCD0103) Alleviates Myocardial Ischemia/Reperfusion Injury via Mitochondrial Protection through the HDACs/CREB/PGC-1alpha Signaling Pathway.	mocetinostat	47-55	cAMP responsive element binding protein 1	Homo sapiens	154-158
34983914-0	2022	Isoform-selective HDAC Inhibitor Mocetinostat (MGCD0103) Alleviates Myocardial Ischemia/Reperfusion Injury via Mitochondrial Protection through the HDACs/CREB/PGC-1alpha Signaling Pathway.	mocetinostat	47-55	PPARG coactivator 1 alpha	Homo sapiens	159-169
34983914-9	2022	Mocetinostat (MGCD0103) can protect myocardium from ischemia/reperfusion injury through mitochondrial protection mediated by CREB/PGC-1alpha pathway.	mocetinostat	0-12	cAMP responsive element binding protein 1	Homo sapiens	125-129
34983914-9	2022	Mocetinostat (MGCD0103) can protect myocardium from ischemia/reperfusion injury through mitochondrial protection mediated by CREB/PGC-1alpha pathway.	mocetinostat	0-12	PPARG coactivator 1 alpha	Homo sapiens	130-140
34983914-9	2022	Mocetinostat (MGCD0103) can protect myocardium from ischemia/reperfusion injury through mitochondrial protection mediated by CREB/PGC-1alpha pathway.	mocetinostat	14-22	cAMP responsive element binding protein 1	Homo sapiens	125-129
34983914-9	2022	Mocetinostat (MGCD0103) can protect myocardium from ischemia/reperfusion injury through mitochondrial protection mediated by CREB/PGC-1alpha pathway.	mocetinostat	14-22	PPARG coactivator 1 alpha	Homo sapiens	130-140
32373984-5	2020	In the current study, the effect of histone deacetylase (HDAC) inhibitor mocetinostat in a rat model of epidural fibrosis was detected, and it was discovered that mocetinostat suppressed myofibroblast activation and increased apoptosis by reducing Akt/GSK3b signaling.	mocetinostat	163-175	glycogen synthase kinase 3 beta	Rattus norvegicus	252-257
32373984-10	2020	In addition, cell assay demonstrated that mocetinostat inhibited fibroblast activation and accelerated apoptosis by inhibiting Akt/GSK3b pathway.	mocetinostat	42-54	AKT serine/threonine kinase 1	Homo sapiens	127-130
32373984-10	2020	In addition, cell assay demonstrated that mocetinostat inhibited fibroblast activation and accelerated apoptosis by inhibiting Akt/GSK3b pathway.	mocetinostat	42-54	glycogen synthase kinase 3 beta	Homo sapiens	131-136
32373984-12	2020	CONCLUSIONS: The above results indicate that mocetinostat inhibits HDAC1 expression and decreases the conduction of the AKT/GSK3b pathway in fibroblasts, leading to myofibroblast activation and apoptosis elevation.	mocetinostat	45-57	histone deacetylase 1	Rattus norvegicus	67-72
32373984-12	2020	CONCLUSIONS: The above results indicate that mocetinostat inhibits HDAC1 expression and decreases the conduction of the AKT/GSK3b pathway in fibroblasts, leading to myofibroblast activation and apoptosis elevation.	mocetinostat	45-57	AKT serine/threonine kinase 1	Rattus norvegicus	120-123
32373984-12	2020	CONCLUSIONS: The above results indicate that mocetinostat inhibits HDAC1 expression and decreases the conduction of the AKT/GSK3b pathway in fibroblasts, leading to myofibroblast activation and apoptosis elevation.	mocetinostat	45-57	glycogen synthase kinase 3 beta	Rattus norvegicus	124-129
31500290-5	2019	We determined that the HDAC1/2/3 inhibitor Mocetinostat synergizes with the HDAC4/5/6 inhibitor LMK-235 in a panel of PDAC cell lines.	mocetinostat	43-55	histone deacetylase 1	Homo sapiens	23-32
31372511-5	2019	Epigenetic-modifying agents such as 5-azacitidine, GSK126 and mocetinostat further reveal cell state-dependent plasticity upon GRHL2 overexpression.	mocetinostat	62-74	grainyhead like transcription factor 2	Homo sapiens	127-132
30867319-5	2019	Suppression of ZEB1 function with miR-200 expression or the histone deacetylase inhibitor mocetinostat sensitized resistant cancer cells to MEK inhibition and markedly reduced in vivo tumor growth, showing a promising combinatorial treatment strategy for KRAS mutant cancers.	mocetinostat	90-102	mitogen-activated protein kinase kinase 7	Homo sapiens	140-143
30344659-0	2018	MGCD0103 induces apoptosis and simultaneously increases the expression of NF-kappaB and PD-L1 in classical Hodgkin"s lymphoma.	mocetinostat	0-8	nuclear factor kappa B subunit 1	Homo sapiens	74-83
29978554-9	2019	MGCD0103 further ameliorated pathological features such as the levels of acetylated histone 3 at Lys 9 site (H3K9) and alpha-tubulin, synaptophysin, Abeta, tau protein phosphorylation, and serotonergic neuron loss against Abeta toxicity.	mocetinostat	0-8	synaptophysin	Mus musculus	134-147
29978554-9	2019	MGCD0103 further ameliorated pathological features such as the levels of acetylated histone 3 at Lys 9 site (H3K9) and alpha-tubulin, synaptophysin, Abeta, tau protein phosphorylation, and serotonergic neuron loss against Abeta toxicity.	mocetinostat	0-8	histocompatibility 2, class II antigen A, beta 1	Mus musculus	149-154
30344659-5	2018	MGCD0103 decreases Bcl-2 levels and upregulates PD-L1, which indicates that the combined use of HDACIs and a PD-L1 inhibitor in theory may improve treatment outcomes in patients with CHL.	mocetinostat	0-8	CD274 molecule	Homo sapiens	48-53
30570744-1	2019	BACKGROUND: The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A binding protein p300 [EP300] histone acetyltransferase genes in a single-arm, open-label phase 2 study.	mocetinostat	34-46	CREB binding protein	Homo sapiens	179-199
30570744-1	2019	BACKGROUND: The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A binding protein p300 [EP300] histone acetyltransferase genes in a single-arm, open-label phase 2 study.	mocetinostat	34-46	CREB binding protein	Homo sapiens	201-207
30344659-0	2018	MGCD0103 induces apoptosis and simultaneously increases the expression of NF-kappaB and PD-L1 in classical Hodgkin"s lymphoma.	mocetinostat	0-8	CD274 molecule	Homo sapiens	88-93
30344659-5	2018	MGCD0103 decreases Bcl-2 levels and upregulates PD-L1, which indicates that the combined use of HDACIs and a PD-L1 inhibitor in theory may improve treatment outcomes in patients with CHL.	mocetinostat	0-8	CD274 molecule	Homo sapiens	109-114
30344659-2	2018	The aim of the present study was to access the class I-selective histone deacetylase (HDAC) inhibitor (HDACI) MGCD0103 on the expression levels of Bcl-2, nuclear factor (NF)-kappaB and programmed death-ligand 1 (PD-L1) in CHL, to explore the possible therapeutic value of MGCD0103 in combined relative target drugs for patients with CHL.	mocetinostat	110-118	BCL2 apoptosis regulator	Homo sapiens	147-152
30344659-2	2018	The aim of the present study was to access the class I-selective histone deacetylase (HDAC) inhibitor (HDACI) MGCD0103 on the expression levels of Bcl-2, nuclear factor (NF)-kappaB and programmed death-ligand 1 (PD-L1) in CHL, to explore the possible therapeutic value of MGCD0103 in combined relative target drugs for patients with CHL.	mocetinostat	110-118	CD274 molecule	Homo sapiens	185-210
30344659-6	2018	MGCD0103 may also up-regulate NF-kappaB, which seems to induce resistance towards anti-apoptotic drugs.	mocetinostat	0-8	nuclear factor kappa B subunit 1	Homo sapiens	30-39
30344659-2	2018	The aim of the present study was to access the class I-selective histone deacetylase (HDAC) inhibitor (HDACI) MGCD0103 on the expression levels of Bcl-2, nuclear factor (NF)-kappaB and programmed death-ligand 1 (PD-L1) in CHL, to explore the possible therapeutic value of MGCD0103 in combined relative target drugs for patients with CHL.	mocetinostat	110-118	CD274 molecule	Homo sapiens	212-217
30344659-4	2018	The results demonstrated that MGCD0103 could induce cell apoptosis and cell cycle arrest, down-regulate Bcl-2 and increase NF-kappaB and PD-L1 expression levels in L1236 and L428 cell lines.	mocetinostat	30-38	BCL2 apoptosis regulator	Homo sapiens	104-109
30344659-4	2018	The results demonstrated that MGCD0103 could induce cell apoptosis and cell cycle arrest, down-regulate Bcl-2 and increase NF-kappaB and PD-L1 expression levels in L1236 and L428 cell lines.	mocetinostat	30-38	nuclear factor kappa B subunit 1	Homo sapiens	123-132
30344659-4	2018	The results demonstrated that MGCD0103 could induce cell apoptosis and cell cycle arrest, down-regulate Bcl-2 and increase NF-kappaB and PD-L1 expression levels in L1236 and L428 cell lines.	mocetinostat	30-38	CD274 molecule	Homo sapiens	137-142
30344659-5	2018	MGCD0103 decreases Bcl-2 levels and upregulates PD-L1, which indicates that the combined use of HDACIs and a PD-L1 inhibitor in theory may improve treatment outcomes in patients with CHL.	mocetinostat	0-8	BCL2 apoptosis regulator	Homo sapiens	19-24
28970362-11	2018	Further supporting the notion that this score accurately reflects HAT activity, we found it is responsive to treatment of cancer cells to mocetinostat, a histone deacetylase (HDAC) inhibitor.Implication: This study provides a rationale for targeted sequencing of EP300 and CREBBP and use of a gene profiling signature for predicting therapeutic response in patients.	mocetinostat	138-150	E1A binding protein p300	Homo sapiens	263-268
28970362-11	2018	Further supporting the notion that this score accurately reflects HAT activity, we found it is responsive to treatment of cancer cells to mocetinostat, a histone deacetylase (HDAC) inhibitor.Implication: This study provides a rationale for targeted sequencing of EP300 and CREBBP and use of a gene profiling signature for predicting therapeutic response in patients.	mocetinostat	138-150	CREB binding protein	Homo sapiens	273-279
28276480-7	2017	We demonstrate that mocetinostat (MGCD0103), a selective HDAC1/HDAC2 inhibitor, is a potent Hh inhibitor and that its effect is linked to Gli1 acetylation at K518.	mocetinostat	34-42	histone deacetylase 2	Mus musculus	63-68
28276480-7	2017	We demonstrate that mocetinostat (MGCD0103), a selective HDAC1/HDAC2 inhibitor, is a potent Hh inhibitor and that its effect is linked to Gli1 acetylation at K518.	mocetinostat	34-42	GLI-Kruppel family member GLI1	Mus musculus	138-142
29124315-7	2018	Mocetinostat synergized with interferon gamma (IFN-gamma) in regulating class II transactivator (CIITA), a master regulator of class II HLA gene expression.	mocetinostat	0-12	class II major histocompatibility complex transactivator	Homo sapiens	72-95
29124315-7	2018	Mocetinostat synergized with interferon gamma (IFN-gamma) in regulating class II transactivator (CIITA), a master regulator of class II HLA gene expression.	mocetinostat	0-12	class II major histocompatibility complex transactivator	Homo sapiens	97-102
29124315-9	2018	In ex vivo assays, patient-derived, mocetinostat-treated Tregs also showed significant down regulation of FOXP3 and HELIOS.	mocetinostat	36-48	forkhead box P3	Homo sapiens	106-111
29124315-9	2018	In ex vivo assays, patient-derived, mocetinostat-treated Tregs also showed significant down regulation of FOXP3 and HELIOS.	mocetinostat	36-48	IKAROS family zinc finger 2	Homo sapiens	116-122
29186204-14	2017	Mocetinostat reduced the expression of gemcitabine-resistance markers RRM1, RRM2, and increased the expression of gemcitabine-sensitivity marker, hENT1, in LMS cells.	mocetinostat	0-12	ribonucleotide reductase catalytic subunit M1	Homo sapiens	70-74
29186204-14	2017	Mocetinostat reduced the expression of gemcitabine-resistance markers RRM1, RRM2, and increased the expression of gemcitabine-sensitivity marker, hENT1, in LMS cells.	mocetinostat	0-12	ribonucleotide reductase regulatory subunit M2	Homo sapiens	76-80
29186204-14	2017	Mocetinostat reduced the expression of gemcitabine-resistance markers RRM1, RRM2, and increased the expression of gemcitabine-sensitivity marker, hENT1, in LMS cells.	mocetinostat	0-12	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	146-151
28560068-8	2017	The HDAC inhibitor mocetinostat showed anti-tumor effects in HDAC2-overexpressing basal-like breast cancer lines in vitro.	mocetinostat	19-31	histone deacetylase 2	Homo sapiens	61-66
28174211-4	2017	For example, the benzamide class I HDAC-selective inhibitor, MGCD0103 [N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl] benzamide], was shown to block cardiac fibrosis, a process involving excess extracellular matrix deposition, which often results in heart dysfunction.	mocetinostat	61-69	histone deacetylase 9	Homo sapiens	35-39
28174211-4	2017	For example, the benzamide class I HDAC-selective inhibitor, MGCD0103 [N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl] benzamide], was shown to block cardiac fibrosis, a process involving excess extracellular matrix deposition, which often results in heart dysfunction.	mocetinostat	71-146	histone deacetylase 9	Homo sapiens	35-39
28276480-7	2017	We demonstrate that mocetinostat (MGCD0103), a selective HDAC1/HDAC2 inhibitor, is a potent Hh inhibitor and that its effect is linked to Gli1 acetylation at K518.	mocetinostat	20-32	histone deacetylase 1	Mus musculus	57-62
28276480-7	2017	We demonstrate that mocetinostat (MGCD0103), a selective HDAC1/HDAC2 inhibitor, is a potent Hh inhibitor and that its effect is linked to Gli1 acetylation at K518.	mocetinostat	20-32	histone deacetylase 2	Mus musculus	63-68
28276480-7	2017	We demonstrate that mocetinostat (MGCD0103), a selective HDAC1/HDAC2 inhibitor, is a potent Hh inhibitor and that its effect is linked to Gli1 acetylation at K518.	mocetinostat	20-32	GLI-Kruppel family member GLI1	Mus musculus	138-142
28276480-7	2017	We demonstrate that mocetinostat (MGCD0103), a selective HDAC1/HDAC2 inhibitor, is a potent Hh inhibitor and that its effect is linked to Gli1 acetylation at K518.	mocetinostat	34-42	histone deacetylase 1	Mus musculus	57-62